OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
48
Results
Show all
Save search
Copy query
Show results for
Unknown
(48)
Publication Date
Release Date
2022
(6)
2020
(6)
2025
(5)
2023
(4)
2021
(4)
2019
(4)
2018
(4)
2017
(4)
2024
(2)
2016
(2)
2015
(2)
2013
(2)
2014
(1)
2012
(1)
2011
(1)
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
Implementation and use of whole exome sequencing for metastatic solid cancer.
Not available
S-EPMC7000332
|
biostudies-literature
Cite
Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours.
Not available
S-EPMC3854123
|
biostudies-literature
Cite
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib.
Not available
S-EPMC11787309
|
biostudies-literature
Cite
Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.
Not available
S-EPMC11739593
|
biostudies-literature
Cite
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Not available
S-EPMC7418426
|
biostudies-literature
Cite
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
Not available
S-EPMC10633948
|
biostudies-literature
Cite
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.
Not available
S-EPMC10992601
|
biostudies-literature
Cite
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
Not available
S-EPMC6593525
|
biostudies-literature
Cite
Real-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry.
Not available
S-EPMC11406442
|
biostudies-literature
Cite
[
123
I]MIBG is a better early marker of anthracycline cardiotoxicity than [
18
F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study.
Not available
S-EPMC8452816
|
biostudies-literature
Cite
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets